CompoAtlas

Whole Food Women's Multi 40+

Texto original en francés.

Producto de salud natural autorizado en Canadá

Si este producto se vendiera en Francia

Solo se calcula una cantidad diaria para una posología oral explícita para adultos, expresada por día y en una unidad sólida correspondiente a la forma del producto. No se extrapolan las unidades ambiguas, los líquidos, los polvos ni las dosis pediátricas. Una cantidad no calculada no se compara con los límites de dosis. Este análisis no constituye una autorización de venta en Francia ni una evaluación de seguridad o eficacia.

Composición

Ingrediente medicinal y fuentePor unidad posológica, según la fuenteMáximo diario, adulto
Lepidium meyenii

Fuente : Racine

7,5 milligrammeNo calculada
Taraxacum officinale

Fuente : Racine

6 milligrammeNo calculada
Vitamine C

Fuente : Acide ascorbique

60 milligramme60.000 µg
Vitamine E

Fuente : Acétate de d-alpha-tocophéryle

Potencia : 30 UI

20 mg ATNo calculada
Thiamine

Fuente : Chlorhydrate de thiamine

2 milligramme2.000 µg
Riboflavine

Fuente : Riboflavine

2 milligramme2.000 µg
Niacinamide

Fuente : Niacinamide

20 milligrammeNo calculada
Vitamine B6

Fuente : Chlorhydrate de pyridoxine

5 milligramme5.000 µg
Biotine

Fuente : Biotine

150 microgrammesNo calculada
Acide pantothénique

Fuente : D-Pantothénate de calcium

10 milligramme10.000 µg
Folate

Fuente : Folate

200 microgrammesNo calculada
Vitamine B12

Fuente : Cyanocobalamine

25 microgrammesNo calculada
Calcium

Fuente : Carbonate de calcium

25 milligramme25.000 µg
Calcium

Fuente : Lithothamnion corallioides - En entier

25 milligramme25.000 µg
Chrome

Fuente : Chlorure de chrome (III)

60 microgrammesNo calculada
Cuivre

Fuente : Sulfate de cuivre (II)

750 microgrammesNo calculada
Iode

Fuente : Iodure de potassium

75 microgrammesNo calculada
Magnésium

Fuente : Oxyde de magnésium

6 milligramme6.000 µg
Magnésium

Fuente : Lithothamnion corallioides - En entier

6 milligramme6.000 µg
Magnésium

Fuente : Carbonate de magnésium

6 milligramme6.000 µg
Manganèse

Fuente : Chlorure de manganèse (II)

1 milligramme1.000 µg
Molybdène

Fuente : Molybdate de sodium (VI)

10 microgrammesNo calculada
Sélénium

Fuente : Sélénate de sodium

75 microgrammesNo calculada
Zinc

Fuente : Oxyde de zinc

7,5 milligramme7.500 µg
Equisetum arvense

Fuente : Sommité

Relación de extracción : 6:1

Equivalente de planta seca : 180 milligramme

30 milligrammeNo calculada
Vitex agnus-castus

Fuente : Fruit

15 milligrammeNo calculada
Ginkgo biloba

Fuente : Feuille

Relación de extracción : 50:1

Equivalente de planta seca : 375 milligramme

Potencia : 24 % Flavonoid glycosides

7,5 milligrammeNo calculada
Ginkgo biloba

Fuente : Feuille

Potencia : 6 % Terpene lactones

No especificadaNo calculada
Hericium erinaceus

Fuente : Mycelia

5 milligrammeNo calculada
Brassica oleracea var. italica

Fuente : Sommité

12,5 milligrammeNo calculada
Vaccinium macrocarpon

Fuente : Fruit

12,5 milligrammeNo calculada
Brassica oleracea var. viridis

Fuente : Feuille

12,5 milligrammeNo calculada
Phyllanthus emblica

Fuente : Fruit

Relación de extracción : 50:1

Equivalente de planta seca : 375 milligramme

7,5 milligrammeNo calculada
Petroselinum crispum

Fuente : Sommité

6 milligrammeNo calculada
Arthrospira platensis

Fuente : Arthrospira platensis - en entier

7,5 milligrammeNo calculada
Withania somnifera

Fuente : Racine

7,5 milligrammeNo calculada
Ophiocordyceps sinensis

Fuente : Stroma

5 milligrammeNo calculada
Inonotus obliquus

Fuente : Mycelia

5 milligrammeNo calculada
Grifola frondosa

Fuente : Mycelia

5 milligrammeNo calculada
Lentinula edodes

Fuente : Mycelia

5 milligrammeNo calculada
Ganoderma lucidum

Fuente : Mycelia

5 milligrammeNo calculada
Echinacée purpurea

Fuente : Sommité

Relación de extracción : 6:1

Equivalente de planta seca : 30 milligramme

5 milligrammeNo calculada
Vitamin K1

Fuente : Vitamine K1

80 microgrammesNo calculada
bêta-carotène

Fuente : bêta-carotène

Potencia : 5.000 UI

3.000 microgrammesNo calculada
Vitamine D

Fuente : Cholécalciférol

Potencia : 1.000 UI

25 microgrammesNo calculada

Ingredientes no medicinales

Acide stéarique, Tapioca, Maltodextrine

Dosis recomendadas en Canadá

PoblaciónEdadCantidad por tomaFrecuencia
AdultesNon précisée1 Comprimé1 Tous les jours

Usos autorizados en Canadá

NHelps to form red blood cells. Helps the body to metabolize carbohydrates, fats and proteins. Helps normal growth and development. Helps in tissue formation. Helps in the development of bones, cartilage, teeth and gums. Helps in connective tissue formation. Helps in wound healing. An antioxidant for the maintenance of good health. Helps in the absorption and use of calcium and phosphorus. Calcium intake, when combined with sufficient vitamin D, a healthy diet, and exercise may reduce the risk of developing osteoporosis. Provides support for healthy glucose metabolism. Helps in the function of the thyroid gland. Source of vitamin A for the maintenance of good health. Source of vitamin A to help maintain eyesight, skin membranes and immune function. Source of vitamin A to help in the development and maintenance of night vision.

Texto original en inglés.

Un uso autorizado en Canadá no es una declaración de propiedades saludables autorizada en la Unión Europea. Consulte el registro de declaraciones de propiedades saludables.

Advertencias en Canadá

Cautions and Warnings : Consult a health care practitioner prior to use if you are taking hormone-containing medications such as progesterone preparation, oral contraceptives or hormone replacement therapy. Consult a health care practitioner prior to use if you are taking medications for diabetes, high blood pressure, or seizures. If you are taking immunosuppressants, consult a health care practitioner prior to use. If you have an autoimmune disorder, consult a health care practitioner prior to use. If you have a progressive systemic disease such as tuberculosis, collagenosis, multiple sclerosis, AIDS and/or HIV infection, consult a health care practitioner prior to use. Consult a health care practitioner prior to use if you have a history of kidney stones. If you have or develop abdominal pain, nausea, fever or vomiting, consult a health care practitioner. If you have liver or gall bladder diseases, and/or intestinal obstruction, consult a health care practitioner prior to use. Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a physician. Consult a health care practitioner prior to use if you are taking health products which may aggravate electrolyte imbalance or are dehydrated. Do not use if you are taking health products that affect blood coagulation (e.g. blood thinners, clotting factor replacements, acetylsalicylic acid, ibuprofen, fish oils, vitamin E) as this may increase the risk of spontaneous bleeding. Do not use if you have oedema due to a kidney or cardiovascular disease. Hypersensitivity/allergy can occur; in which case, discontinue use. Rare cases of severe allergic reactions have been known to occur. Use caution if you are allergic to plants of the Daisy family. Laxative effect may occur, in which case, discontinue use. Consumption with alcohol, other drugs or natural health products with sedative properties is not recommended.

Texto original en inglés.

Ficha del producto

Titular
WN Pharmaceuticals Ltd
NPN o DIN-HM
80068509
Estado
Licencia activa
Fecha de licencia
13 de abril de 2016
Fecha de revisión
24 de mayo de 2024
Forma
Comprimé
Vía de administración
Orale
Tipo de solicitud
Non traditionnelle

Fuente

Ficha oficial de Health Canada, licencia 80068509

Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias, consultado el 27 de octubre de 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Texto original en inglés.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Texto original en francés.

La fórmula vendida en Europa con el mismo nombre puede ser diferente. Esta información no sustituye el consejo de un médico o farmacéutico.

Advertencias oficiales (Health Canada)

Health Canada publica advertencias sobre estos ingredientes:

  • Lepidium meyenii
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    Maca - Lepidium Meyenii

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Se aplica a los productos: providing 0.6 g or more dried root/hypocotyl, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a blood pressure condition (Valentova et al. 2008).

    Fuentes citadas por Health Canada (1)
    • Valentova K, Stejskal D, Bartek J, Dvoráckova S, Kren V, Ulrichova J, Simanek V. Maca (Lepidium meyenii) and yacon (Smallanthus sonchifolius) in combination with silymarin as food supplements: in vivo safety assessment. Food and Chemical Toxicology 2008;46(3):1006-1013. PubMed Ensayo aleatorizado

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).

    Fuentes citadas por Health Canada (2)
    • Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Ensayo aleatorizado
    • Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed

    Condición de aplicación: Healthy mood balance; Sexual health.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression (Brotto 2010; Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).

    Fuentes citadas por Health Canada (3)
    • Brotto LA. The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Archives of Sexual Behavior 2010;39(2):221-239. PubMed Artículo de revisión
    • Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Ensayo aleatorizado
    • Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed

    Monografía de Health Canada del 27 de septiembre de 2024

  • Vitex agnus-castus
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    CHASTE TREE - VITEX AGNUS-CASTUS

    Vía de administración: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).

    Fuentes citadas por Health Canada (4)
    • Bradley PR, editor. 2006. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
    • OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.

    Contraindicaciones

    Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).

    Fuentes citadas por Health Canada (9)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. 2000. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dugoua JJ, Seely D, Pern D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex Agnus-Castus) during pregnancy and lactation. Can J. Clin Pharmacol 2008;15(1);e74-e79.
    • EMA 2018. European Medicines Agency. European Union herbal monograph on Vitex agnus-castus L., fructus. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 27 March 2018. [Accessed 2024 February 29] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy in collaboration with Thieme.
    • Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.
    • Najib FS, Poordast T, Mahmudi MS, Shiravani Z, Namazi N, Omrani GR. Does Vitex Agnus-Castus L. Have Deleterious Effect on Fertility and Pregnancy Outcome? An Experimental Study on Rats for Prediction of Its Safety. J. Pharmacopuncture 2022;25(2):106-113. PubMed
    • WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
    • OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.

    Monografía de Health Canada del 28 de marzo de 2024

  • Ginkgo biloba
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    GINKGO - GINKGO BILOBA

    Vía de administración: Oral

    Precauciones y advertencias

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).

    Fuentes citadas por Health Canada (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
    • WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
    • OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).

    Fuentes citadas por Health Canada (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Contraindicaciones

    Do not use if you are having a surgery (Gardner and McGuffin 2013).

    Fuentes citadas por Health Canada (1)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).

    Fuentes citadas por Health Canada (3)
    • Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Revisión sistemática
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Monografía de Health Canada del 25 de julio de 2025

  • Vaccinium macrocarpon
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    CRANBERRY - VACCINIUM MACROCARPON

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Fuentes citadas por Health Canada (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Ensayo aleatorizado
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Fuentes citadas por Health Canada (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Caso clínico
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Condición de aplicación: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 27 de marzo de 2026

    DRIED CRANBERRY JUICE

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Fuentes citadas por Health Canada (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Ensayo aleatorizado
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Fuentes citadas por Health Canada (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Caso clínico
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Condición de aplicación: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografía de Health Canada del 27 de marzo de 2026

  • Phyllanthus emblica
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    Amla - Phyllanthus Emblica

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).

    Fuentes citadas por Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Se aplica a los productos: providing more than 3 grams of amla, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).

    Fuentes citadas por Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Condición de aplicación: Amlapitta, Digestive tonic.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condición de aplicación: Laxative.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).

    Fuentes citadas por Health Canada (3)
    • CPhA 2002: Repchinsky C, editor-in-chief. Patient Self-Care: Helping Patients Make Therapeutic Choices. 1st edition. Ottawa (ON): Canadian Pharmacists Association; 2002.
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
    • Pray WS. Non-Prescription Product Therapeutics. 2nd edition. New York (NY): Lippincott Williams & Wilkins; 2006.

    Contraindicaciones

    Condición de aplicación: Laxative.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).

    Fuentes citadas por Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Reacciones adversas conocidas

    Condición de aplicación: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.

    When using this product you may experience a laxative effect.

    Monografía de Health Canada del 28 de marzo de 2025

  • Withania somnifera
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    ASHWAGANDHA - WITHANIA SOMNIFERA

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).

    Fuentes citadas por Health Canada (3)
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).

    Fuentes citadas por Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
    • Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.

    Monografía de Health Canada del 28 de febrero de 2025

  • Vitamine D
    Leer la advertencia, cuándo se aplica y los estudios citados

    Texto original oficial en inglés.

    VITAMIN D (>1,000 - 2,500 IU)

    Vía de administración: Oral

    Precauciones y advertencias

    Condición de aplicación: All products except products containing zinc sourced from picolinate requiring a contraindication.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condición de aplicación: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney disorders (NIH 2024; BfR 2020).

    Fuentes citadas por Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other supplements or products containing vitamin D or vitamin D analogues.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any medications including antacids, anticonvulsants, digoxin, cholestyramine, colestipol, mineral oil, steroids, statins or thiazide diuretics (NNHPD 2021; BfR 2020).

    Fuentes citadas por Health Canada (3)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NNHPD 2021. Natural and Non-Prescription Health Products Directorate. Internal evidence and HC's product monographs.
    • DPSNSO 2021. Direction des produits de santé naturels et sans ordonnance. Preuves internes et monographies de produits internes de SC.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to determine if you would benefit from additional vitamin D as 15-20 mcg (600-800 IU) of vitamin D per day is an adequate quantity for most individuals.

    Se aplica a los productos: containing vitamin K2.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (NNHPD 2026).

    Fuentes citadas por Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Se aplica a los productos: providing 25-34 mg of zinc per day for adults 18 years or 31-50 mg of zinc per day for adults 19 years and older.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are unsure whether you are taking enough copper as zinc supplementation can cause a copper deficiency (NNHPD 2026).

    Fuentes citadas por Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Contraindicaciones

    Condición de aplicación: All products.

    Do not use if you have hypercalcemia and/or hypercalciuria (NIH 2024; BfR 2020).

    Fuentes citadas por Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Se aplica a los productos: containing zinc sourced from picolinate.

    Do not use if you are pregnant or breastfeeding (NNHPD 2026).

    Fuentes citadas por Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Reacciones adversas conocidas

    Condición de aplicación: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if the following early symptoms of hypercalcemia occur: weakness, fatigue, drowsiness, headache, lack of appetite, dry mouth, metallic taste, nausea, vomiting, vertigo, ringing in the ears, lack of coordination and muscle weakness or if you develop any other symptom (NIH 2024; BfR 2020).

    Fuentes citadas por Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Se aplica a los productos: providing more than 350 mg of magnesium per day.

    When using this product you may experience diarrhea (NNHPD 2026).

    Fuentes citadas por Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Monografía de Health Canada del 26 de junio de 2026

Se refieren al ingrediente, no a este producto ni a su dosis. No sustituyen el consejo médico.

Lista en la revisión oficial del (registro: Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias).

Fotografiar el envase

¿Alguna información inexacta o más reciente sobre este producto, sea usted lector o marca? Escriba a contact@compoatlas.com: cada corrección se publica en el registro de correcciones.

Lista registrada en 2024. Fotografíe el envase para comprobar si ha cambiado.

Intro para analizar, Mayús+Intro para una nueva línea